+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Small Cell Lung Cancer (SCLC) - Market Insights, Epidemiology and Market Forecast - 2030

  • ID: 5023868
  • Drug Pipelines
  • May 2020
  • Region: Global
  • 200 pages
  • DelveInsight

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • EpicentRx
  • Merck
  • PharmaMar
This report delivers an in-depth understanding of the SCLC, historical and forecasted epidemiology as well as the SCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

The SCLC market report provides current treatment practices, emerging drugs, SCLC market share of the individual therapies, current and forecasted SCLC market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current SCLC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2030

Small Cell Lung Cancer (SCLC) Disease Understanding and Treatment Algorithm

Small Cell Lung Cancer Overview

Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC, the more common). The treatment method is different for both types.

SCLC spreads (metastasizes) much faster than NSCLC to other organs, whereas microscopically, SCLC is composed of much smaller cells. SCLC can be fatal in a few weeks if untreated, in contrast to most cases of NSCLC. Also, NSCLC accounts for about 80-85% of lung cancers.

SCLC is an aggressive disease with distinct pathological, clinical, and molecular characteristics along with having a high metastatic potential that results in clinically poor prognosis, which is not the case for NSCLC. SCLC is also known as ‘oat-cell' cancer because the cells look like oats under the microscope. It often starts in the bronchi, then quickly grows and spread to other parts of the body, including the lymph nodes. This type of lung cancer represents about 15% of lung cancers and is typically caused by tobacco smoking. SCLC tends to spread quite early and it can also be classed as neuroendocrine tumors. It has been observed that about three-quarters of SCLC patients are diagnosed with extensive-stage disease.

“Extensive-stage SCLC patients who progress after platinum-based chemotherapy are traditionally categorized as platinum sensitive (progression ≥ 90 days from last platinum dose) or refractory (progression < 90 days).”

Small Cell Lung Cancer Diagnosis

The diagnosis of cancer mainly starts with a different set of tests that can be performed to examine cancer or for its better and effective treatment. They may start off by examining the extent of cancer metastasis, which can be done by analyzing what other parts of the body are affected apart from the point of initiation. For example, imaging tests - that displays the internal picture of the body - can indicate if cancer has spread, but they can never be used alone to diagnose SCLC.

A biopsy is recommended as it the only way for the doctor to confirm the presence of cancer; however, there are other methods also, if biopsy cannot be performed.

The doctor may consider these factors when choosing a diagnostic test:
  • Size, location, and type of cancer suspected
  • Signs and symptoms
  • Age and general health
  • The results of earlier medical tests
Small Cell Lung Cancer Treatment

The treatment of SCLC mainly starts with a combination of chemotherapy and immunotherapy, and may also include radiation therapy and surgery. The treatment options and recommendations of SCLC depend on factors like the type and stage of cancer, possible side effects, and the patient's preferences and overall health. Treatment for symptoms and side effects form an essential part of cancer care.

Small Cell Lung Cancer Epidemiology

The Small Cell Lung Cancer epidemiology division provide the insights about historical and current Small Cell Lung Cancer patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

Total incident cases of SCLC in the 7MM was assessed to be 85,540 in 2017, and are expected to increase during the study period. The increase is partly credited to the rising trend in incidence in the 7MM, combined with underlying demographic changes in the respective markets. Furthermore, the total incident cases of SCLC patients were found to be more in males than in females in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Small Cell Lung Cancer epidemiology [segmented as Total Incident Patient Population, Gender-specific Incident Patient Population, Age-specific Incident Patient Population, Stage-Specific Incident Population, and Line-wise Treatment of Extensive-Stage SCLC (first-line, second-line platinum sensitive, second-line platinum refractory, and third-line and above] scenario of Small Cell Lung Cancer in 7MM covering United States, EU5 countries (Germany, France, Italy , Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- Small Cell Lung Cancer Epidemiology

Among the European 5 countries, Germany had highest incident population of SCLC, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident cases of SCLC.

Small Cell Lung Cancer Drug Chapters

Drug chapter segment of the Small Cell Lung Cancer report encloses the detailed analysis of Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Small Cell Lung Cancer Marketed Drugs

Opdivo (Nivolumab): Bristol-Myers Squibb
Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. It is a prescription medicine used to treat people with unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer and hepatocellular carcinoma. It is not known if Opdivo is safe and effective in children younger than 18 years of age. This drug is approved under accelerated approval based on overall response rate and duration of response for patients with metastatic small cell lung cancer with progression after platinum-based chemotherapy and at least one other line of therapy. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Keytruda (Pembrolizumab): Merck
Keytruda, also known as pembrolizumab, is a programmed death receptor-1 (PD-1)-blocking antibody. It is mainly used for cancers that are advanced, have spread to other parts of the body (metastatic) or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high levels of a protein known as PD-L1. This drug is also used to help prevent the cancer from coming back after patients had surgery to remove melanoma (adjuvant therapy).

Products detail in the report.

Small Cell Lung Cancer Emerging Drugs

Imfinzi +/- tremelimumab: AstraZeneca
Imfinzi (Durvalumab) also known as medi4736 with or without tremelimumab, is under development by AstraZeneca. It is administered intravenously after completing a combination of chemotherapy and radiation therapy (CRT) given at the same time, also known as concurrent CRT. Imfinzi may also attack healthy cells. It binds to a protein called PD-L1, which is found on some cancer cells and may block this protein and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor.

In 2017, AstraZeneca initiated a phase III, randomized, multicenter, open-label, and comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive stage SCLC (CASPIAN). In addition to this, the company also initiated a phase III, randomized, double-blind, placebo-controlled, multi-center, international study of durvalumab or durvalumab and tremelimumab as consolidation treatment for patients with limited-stage SCLC who have not progressed following concurrent chemoradiation therapy

Lurbinectedin (PM01183): PharmaMar
Lurbinectedin (Zepsyre, PM1183) by PharmaMar, is a compound in clinical research that belongs to the RNA polymerase II enzyme inhibitors family, which is essential for the transcription process. By inhibiting transcription, the compound reduces the expression of certain factors that are involved in tumor progression and blocks the DNA repair system called NER. This eventually induces the death of tumor cells. The antitumor efficacy of PM1183 (lurbinectedin) is being investigated in several types of tumors. Currently it is in phase III clinical developmental trial for SCLC.

RRx-001: EpicentRx
EpicentRx is developing its lead program RRx-001, which is among a portfolio of immunotherapeutic compounds that normalize the tumor microenvironment, activate the tumor associated macrophages (TAMs) of the innate immune system, and sensitize solid tumors to standard therapies in small cell lung cancer (SCLC), glioblastoma, colorectal cancer and additional cancers. It is a next generation, small molecule anticancer immunotherapeutic that down regulates the CD47/SIRPα axis and repolarizes TAMs and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype. RRx-001 is designed to be used either as a monotherapy or in combination with chemotherapy, radiation therapy or immunotherapy. It has been granted Orphan Drug Designation from the US FDA and EMA for the treatment of patients with small cell lung cancer.

Products detail in the report.

Small Cell Lung Cancer Market Outlook

The management of SCLC is problematic due to the aggressive nature of this type of cancer. Another reason behind the complex treatment of SCLC is frequent substantial comorbidities caused by smoking, and impaired performance status, which make it more challenging for the patients with SCLC to receive appropriate treatment. As previously mentioned, SCLC has two stages. Among those, LS-SCLC is typically treated with a combined modality therapy of radiation therapy and chemotherapy. The recommended systemic chemotherapy is the combination of etoposide and cisplatin, administered concomitantly with thoracic irradiation. There may also be a role for surgery in the management of patients with very early-stage SCLC, generally without nodal involvement. Besides this, the combination of radiotherapy and cisplatin-based chemotherapy is the standard of care for LS-SCLC. Three anti-PD-1 antibodies, Atezolizumab (Tecentriq; Hoffmann-La Roche - Genentech), Nivolumab (Opdivo; Bristol-Myers Squibb) and Pembrolizumab (Keytruda; Merck Sharp & Dohme Corp), have been approved for the treatment of SCLC. They block the inhibitory receptor on tumor-infiltrating T cells and regulate the adaptive immune system to exert antitumor response. Among all the above-mentioned Immunotherapies, atezolizumab (Tecentriq; Bristol-Myers Squibb) is the only one which is approved in the US, Europe, and Japan [US: (March 2019) - EU: (September 2019) - JP: (August 2019)] for initial treatment of ES-SCLC.

Key Findings

According to the publisher, Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Small Cell Lung Cancer in seven major markets is expected to generate USD 337 million in 2017 and will increase in the study period 2017-2030.

In 2017, the revenue generated in Second line platinum sensitive extensive SCLC was around USD 64 Million. Furthermore, the revenue of Second line platinum resistant extensive SCLC was around 15% of the overall market size.

The United States Market Outlook

Among the 7MM countries, the United States had the highest market size of SCLC in 2017.

EU-5 Countries: Market Outlook

The total Small Cell Lung Cancer market Size and market Size by therapies in Germany, France, Italy, Spain and the United Kingdom is provided in this section.

Japan Market Outlook

Like other 7MM countries, at present, the therapeutic landscape for SCLC in Japan is dependent on current treatment regimens. Assessments show the market size is likely to propel by the end of 2030, starting with USD 54 million in 2017.

Small Cell Lung Cancer Drugs Uptake

Currently, market is mainly driven by chemotherapeutic agents as SCLC patients in the US mostly receive Platinum plus etoposide combination therapy. And within the regimen, combination of carboplatin plus etoposide is the gold standard treatment across the US, EU5 and JP, cisplatin plus etoposide was more common in the EU5 compared with the US or Japan. Tecentriq (atezolizumab) and Imfinzi (durvalumab) expected to dominate the market in future due to targeting of broader pool of patients (i.e. first line treatment setting) and expected less completion in first line setting

Small Cell Lung Cancer Pipeline Development Activities

The drugs which are in pipeline includes:

1. Lurbinectedin (PM01183): PharmaMar: Phase III

2. Imfinzi +/- tremelimumab: AstraZeneca: Phase III (SCLC (limited-stage/ Extensive Disease/ Recurrent/ Platinum Refractory Extensive-Stage)

3. RRx-001: EpicentRx: Phase III

4. Dinutuximab (Unituxin): United Therapeutics: Phase II/III

Products detail in the report.

Pipeline Development Activities

Key Points

1. In March 2020, AstraZeneca's Imfinzi has been approved in the United States as a 1st-line treatment for adult patients with ES-SCLC in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide) (AstraZeneca, 2020). Imfinzi is currently under clinical investigation for Limited and extensive-stage SCLC and not yet approved in any markets outside of the United States.

2. In December 2019, the company submitted to NDA to the US FDA in the United States for lurbinectedin for the treatment of patients with SCLC who have progressed after prior platinum-containing therapy, under the accelerated approval regulations.

3. In November 2019, EpicentRx Initiated dosing in phase III trial of immunotherapy RRx-001 for third-line small cell lung cancer. REPLATINUM is EpicentRx's first Phase III study of RRx-001, a small molecule immunotherapy targeting CD47 - SIRPα.

Reimbursement Scenario in Small Cell Lung Cancer

In January 2020, the National Institute for Health and Care Excellence (NICE) proposed that Tecentriq in combination with carboplatin and etoposide shouldn't be made available for untreated extensive-stage SCLC in adults.

According to the guidance, it was noted that clinical data show that Tecentriq plus chemotherapy “could help people to live longer without their disease progressing, and to live for longer compared with chemotherapy alone”. Also, the agency said that “the cost-effectiveness estimates for atezolizumab with chemotherapy are higher than what is considered a cost-effective use of NHS resources”. So, it should not be available for SCLC via the Cancer Drugs Fund - which provides a backup route for patient access to drugs while new evidence is being generated - although NICE notes that Roche “did not express an interest in the treatment being considered for funding” via the CDF.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Small Cell Lung Cancer Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Small Cell Lung Cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Small Cell Lung Cancer market
Report Highlights
  • In the coming years, Small Cell Lung Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Small Cell Lung Cancer. Launch of emerging therapies, will significantly impact the Small Cell Lung Cancer market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Small Cell Lung Cancer
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Small Cell Lung Cancer Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Small Cell Lung Cancer Pipeline Analysis
  • Small Cell Lung Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Small Cell Lung Cancer Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
Small Cell Lung Cancer Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Small Cell Lung Cancer Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the Small Cell Lung Cancer Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Small Cell Lung Cancer total market Size as well as market Size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Small Cell Lung Cancer market Size during the study period (2017-2030)?
  • At what CAGR, the Small Cell Lung Cancer market is expected to grow in 7MM during the study period (2017-2030)?
  • What would be the Small Cell Lung Cancer market outlook across the 7MM during the study period (2017-2030)?
  • What would be the Small Cell Lung Cancer market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • How the market size looks like by line of therapies (LoTs) for each 7MM country? And what are the treatment options for each line of therapy and revenue these treatment options expected to garner?
  • How many patients are responding to Platinum therapy after progression from first-line (% patients with Platinum Sensitive and Platinum Refractory)?
  • What are the treatment options for Platinum Sensitive and Platinum Refractory patient pool?
  • Which patient segment or line of therapy is more lucrative in SCLC? And where the emerging therapies are focusing more?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the Small Cell Lung Cancer?
  • What is the historical Small Cell Lung Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Small Cell Lung Cancer in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Small Cell Lung Cancer?
  • Out of all 7MM countries, which country would have the highest Incident population of Small Cell Lung Cancer during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the study period (2017-2030)?
  • What are the current available treatments of limited and extensive Small Cell Lung Cancer? And how the prescription patters look like across the various line of therapies (LoTs) and how does it differ across the 7MM?
  • Between the limited and extensive SCLC, majority of patients are diagnosed with which condition?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the treatment of Small Cell Lung Cancer along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Small Cell Lung Cancer in US, Europe and Japan?
  • What are the Small Cell Lung Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Small Cell Lung Cancer?
  • How many therapies are developed by each company for the treatment of Small Cell Lung Cancer?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Small Cell Lung Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Small Cell Lung Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for Small Cell Lung Cancer?
  • What are the global historical and forecasted market of Small Cell Lung Cancer?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Small Cell Lung Cancer market
  • To understand the future market competition in the Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Small Cell Lung Cancer in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Small Cell Lung Cancer market
  • To understand the future market competition in the Small Cell Lung Cancer market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • EpicentRx
  • Merck
  • PharmaMar
1. Key Insights

2. Executive Summary of SCLC

3. SWOT Analysis for SCLC

4. SCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of SCLC in 2017
4.2. Total Market Share (%) Distribution of SCLC in 2030

5. Small Cell Lung Cancer (SCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Signs and Symptoms of Lung Cancer
5.1.2. Risk Factors of SCLC
5.1.3. Causes of SCLC
5.1.4. Disease Biology: SCLC
5.2. Diagnosis of Small-cell Lung Cancer (SCLC)
5.2.1. Imaging tests
5.2.2. Staging in SCLC

6. Epidemiology and Patient Population
6.1. Epidemiology Key Findings
6.2. Assumptions and Rationale: 7MM
6.3. Total Incidence of Lung Cancer in the 7MM
6.4. Total Incidence cases of SCLC in the 7MM

7. United States
7.1. Total Incidence cases of SCLC in the United States
7.2. Gender-specific Incidence of SCLC in the United States
7.3. Age-specific Incidence of SCLC in the United States
7.4. Stage-Specific Incidence of SCLC in the United States
7.5. Line-wise Treatment of Extensive-Stage SCLC in the United States

8. EU-5 Country-wise Epidemiology
8.1. Germany
8.1.1. Total Incidence cases of SCLC in Germany
8.1.2. Gender-specific Incidence of SCLC in Germany
8.1.3. Age-specific Incidence of SCLC in Germany
8.1.4. Stage-Specific Incidence of SCLC in Germany
8.1.5. Line-wise Treatment of Extensive-Stage SCLC in Germany
8.2. France
8.2.1. Total Incidence cases of SCLC in France
8.2.2. Gender-specific Incidence of SCLC in France
8.2.3. Age-specific Incidence of SCLC in France
8.2.4. Stage-Specific Incidence of SCLC in France
8.2.5. Line-wise Treatment of Extensive-Stage SCLC in France
8.3. Italy
8.3.1. Total Incidence cases of SCLC in Italy
8.3.2. Gender-specific Incidence of SCLC in Italy
8.3.3. Age-specific Incidence of SCLC in Italy
8.3.4. Stage-Specific Incidence of SCLC in Italy
8.3.5. Line-wise Treatment of Extensive-Stage SCLC in Italy
8.4. Spain
8.4.1. Total Incidence cases of SCLC in Spain
8.4.2. Gender-specific Incidence of SCLC in Spain
8.4.3. Age-specific Incidence of SCLC in Spain
8.4.4. Stage-Specific Incidence of SCLC in Spain
8.4.5. Line-wise Treatment of Extensive-Stage SCLC in Spain
8.5. United Kingdom
8.5.1. Total Incidence cases of SCLC in the United Kingdom
8.5.2. Gender-specific Incidence of SCLC in the United Kingdom
8.5.3. Age-specific Incidence of SCLC in the United Kingdom
8.5.4. Stage-Specific Incidence of SCLC in the United Kingdom
8.5.5. Line-wise Treatment of Extensive-Stage SCLC in the United Kingdom

9. Japan
9.1. Total Incidence cases of SCLC in Japan
9.2. Gender-specific Incidence of SCLC in Japan
9.3. Age-specific Incidence of SCLC in Japan
9.4. Stage-Specific Incidence of SCLC in Japan
9.5. Line-wise Treatment of Extensive-Stage SCLC in Japan

10. Current Treatment Practices for Small-cell Lung Cancer (SCLC)
10.1. Management Algorithm of SCLC
10.2. SCLC Treatment Paradigm
10.3. Radiation Therapy
10.4. Surgery
10.5. Metastatic Lung Cancer
10.6. Remission and the Chance of Recurrence
10.7. Guidelines for SCLC
10.7.1. Treatment Differences across 7MM
10.7.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
10.7.3. The American College of Chest Physicians (ACCP) Clinical Practice Guidelines: SCLC

11. Patient Journey

12. Unmet Needs

13. Key Endpoints in SCLC Clinical Trials

14. Marketed Products
14.1. Opdivo (Nivolumab): Bristol-Myers Squibb/ Ono Pharmaceutical
14.1.1. Product Description
14.1.2. Regulatory Milestones
14.1.3. Other Developmental Activities
14.1.4. Pivotal Clinical Trials
14.1.5. Ongoing Clinical Trials Information
14.1.6. Safety and Efficacy of Ongoing Trials
14.2. Keytruda (Pembrolizumab): Merck
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Clinical Trials Information
14.2.6. Safety and Efficacy of Ongoing Trials
14.3. Tecentriq (Atezolizumab): Hoffmann-La Roche
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Clinical Trials Information
14.3.6. Safety and Efficacy of Ongoing Clinical Trials

15. Emerging Therapies
15.1. Key Cross
15.2. Imfinzi +/- tremelimumab: AstraZeneca
15.2.1. Product Description
15.2.2. Regulatory Milestones
15.2.3. Other Developmental Activities
15.2.4. Clinical Development
15.2.5. Safety and Efficacy
15.3. Lurbinectedin (PM01183): PharmaMar
15.3.1. Product Description
15.3.2. Other Developmental Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. RRx-001: EpicentRx
15.4.1. Product Description
15.4.2. Other Developmental Activities
15.4.3. Clinical Development
15.4.4. Safety and Efficacy
15.5. Dinutuximab (Unituxin): United Therapeutics
15.5.1. Product Description
15.5.2. Other Developmental Activities
15.5.3. Clinical Development
15.5.4. Safety and Efficacy
15.6. Irinotecan liposome injection: Ipsen
15.6.1. Product Description
15.6.2. Other Developmental Activities
15.6.3. Clinical Development
15.6.4. Safety and Efficacy
15.7. Trilaciclib (G1T28): G1 Therapeutics
15.7.1. Product Description
15.7.2. Other Developmental Activities
15.7.3. Clinical Development
15.7.4. Safety and Efficacy
15.8. Dendritic Cell-based p53 Vaccine + Nivolumab + Ipilimumab: MultiVir
15.8.1. Product Description
15.8.2. Other Developmental Activities
15.8.3. Clinical Development
15.8.4. Safety and Efficacy
15.9. Guadecitabine + Carboplatin: Otsuka Holdings
15.9.1. Product Description
15.9.2. Other Developmental Activities
15.9.3. Clinical Development
15.10. Iclusig (ponatinib): Takeda
15.10.1. Product Description
15.10.2. Other Developmental Activities
15.10.3. Clinical Development
15.10.4. Safety and Efficacy

16. Conjoint Analysis of Small Cell Lung Cancer (SCLC) Therapies

17. Small Cell Lung Cancer (SCLC): Seven Major Market Analysis
17.1. Key Findings
17.2. Market Outlook: 7MM
17.3. Total Market Size of SCLC in the 7MM
17.4. Market Size of SCLC by Therapeutic Class in the 7MM

18. United States Market Size
18.1. Total Market size of SCLC in the United States

19. EU-5 Market Size
19.1. Germany Market Size
19.1.1. Total Market size of SCLC in Germany
19.2. France Market Size
19.2.1. Total Market size of SCLC in France
19.3. Italy Market Size
19.3.1. Total Market size of SCLC in Italy
19.4. Spain Market Size
19.4.1. Total Market size of SCLC in Spain
19.5. United Kingdom Market Size
19.5.1. Total Market size of SCLC in the United Kingdom

20. Japan Market Size
20.1. Total Market size of SCLC in Japan

21. Market Access and Reimbursement Scenario of SCLC Therapies

22. Market Drivers

23. Market Barriers

24. Appendix
24.1. Bibliography
24.2. Report Methodology

25. Disclaimer

26. The Publisher's Capabilities

27. About the Publisher
Note: Product cover images may vary from those shown
  • Bristol-Myers Squibb
  • Merck
  • AstraZeneca
  • PharmaMar
  • EpicentRx
Note: Product cover images may vary from those shown
Adroll
adroll